I. Kocák

发表

[Possibilities of resistance prediction to neoadjuvant concomitant chemoradiotherapy in the treatment algorithm of patients with rectal carcinoma].

R. Vyzula, P. Fabián, O. Slabý, 2008, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

Randomized phase II study of AKT blockade with ipatasertib (GDC-0068) and abiraterone (Abi) vs. Abi alone in patients with metastatic castration-resistant prostate cancer (mCRPC) after docetaxel chemotherapy (A. MARTIN Study).

J. Bono, R. Meng, A. Font, 2016 .

Treatment of non-metastatic castration-resistant prostate cancer

I. Kocák, 2021, Urologie pro praxi.

Oligometastatic Prostate Cancer.

A. Poprach, R. Vyzula, R. Lakomy, 2019, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response.

J. Kovarik, L. Dušek, I. Kocák, 2002, Neoplasma.

Combined therapy of locally advanced rectal adenocarcinoma with capecitabine and concurrent radiotherapy.

R. Vyzula, M. Svoboda, I. Kocáková, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial.

C. Redfern, N. Clarke, J. Jassem, 2022, The Lancet. Oncology.

First-line use of cabazitaxel in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (mCRPC): A three-arm study in comparison with docetaxel.

V. Kataja, C. Théodore, P. Mainwaring, 2012 .

Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial.

F. Saad, C. Redfern, N. Clarke, 2018, The Lancet. Oncology.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

J. Machiels, S. Hansen, S. Oudard, 2010, The Lancet.

PTEN loss as a predictive biomarker for the Akt inhibitor ipatasertib combined with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC)

J. Bono, M. Wongchenko, A. Font, 2016 .

Sunitinib-Induced Elevation of Mean Corpuscular Volume (MCV)—Exploring Its Possible Clinical Relevance in Cancer Patients

J. Štěrba, I. Selingerová, I. Kocáková, 2022, Current oncology.

Impact of Cabazitaxel (CBZ) + Prednisone (P; CBZP) on Overall Survival (OS) At 2 Yrs and in Patients (PTS) with Aggressive Disease: Post-Hoc Analyses of Tropic Trial

J. Machiels, J. Bono, S. Oudard, 2012 .

[Epidemiological and clinico-pathological characteristics of patients with renal carcinoma: a single institution analysis of 544 cases].

A. Poprach, T. Pavlík, Z. Bortlíček, 2013, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

Detection and Long-Term In Vivo Monitoring of Individual Tumor-Specific T Cell Clones in Patients with Metastatic Melanoma1

J. Michálek, R. Hájek, I. Kocák, 2007, The Journal of Immunology.

MelanomaCell Clones in Patients with Metastatic Monitoring of Individual Tumor-Specific T Detection and Long-Term In Vivo

J. Michálek, R. Hájek, I. Kocák, 2007 .

A phase I/II study of siltuximab (CNTO 328), an anti-interleukin-6 monoclonal antibody, in metastatic renal cell cancer

J. Rossi, N. James, U. Prabhakar, 2010, British Journal of Cancer.

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

B. Tombal, S. Oudard, G. Gravis, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation.

J. Kovarik, V. Boudný, I. Kocák, 2003, International journal of molecular medicine.

Phase II monotherapy study of YM155, a novel survivin suppressant, administered by 168-hour continuous infusion in previously treated hormone refractory prostate cancer (HRPC)

G. Hudes, D. Quinn, A. Mita, 2007 .

Vinorelbine, epirubicin, and methotrexate (VEM) as primary treatment in locally advanced breast cancer.

J. Abrahámová, I. van Praagh, E. Simova, 2001, The oncologist.

Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry.

B. Melichar, L. Dušek, Z. Bortlíček, 2015, Anticancer research.

Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients.

J. Kovarik, V. Boudný, I. Kocák, 2003, Folia biologica.

F. Saad, C. Redfern, N. Clarke, 2019, Journal of Clinical Oncology.

Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.

R. Jones, F. Saad, C. Redfern, 2018 .

Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA).

D. Amadori, S. Fosså, A. Haese*, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Overall Survival Benefit of Radium-223 Chloride (Alpharadin™) in the Treatment of Patients with Symptomatic Bone Metastases in Castration-resistant Prostate Cancer (CRPC): a Phase III Randomized Trial (ALSYMPCA)

D. Amadori, S. Fosså, C. Parker, 2011 .

Neoadjuvant treatment for locally advanced rectal adenocarcinoma with concomitant radiotherapy and oral capecitabine.

I. Kocáková, P. Čoupek, I. Kocák, 2004, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute].

A. Poprach, R. Vyzula, M. Svoboda, 2009, Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti.

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

J. Machiels, S. Hansen, S. Oudard, 2010, The Lancet.

Prognostic factors for survival in the phase III TROPIC trial.

S. Oudard, I. Bodrogi, G. Gravis, 2012, Journal of Clinical Oncology.